 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | SCRI-huCAR19v1 / Seattle Children's Hospital, SCRI-huCAR19v2 / Seattle Children's Hospital
Enrollment closed, Enrollment change, CAR T-Cell Therapy: CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma (clinicaltrials.gov) - Feb 10, 2021
P1/2, N=16, Active, not recruiting, Sponsor: Seattle Children's Hospital
Suspended --> Active, not recruiting | N=112 --> 16
- | SCRI-huCAR19v1 / Seattle Children's Hospital, SCRI-huCAR19v2 / Seattle Children's Hospital
Trial suspension, CAR T-Cell Therapy: CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma (clinicaltrials.gov) - Jan 26, 2021
P1/2, N=112, Suspended, Sponsor: Seattle Children's Hospital
Suspended --> Active, not recruiting | N=112 --> 16 Recruiting --> Suspended
- | SCRI-huCAR19v1 / Seattle Children's Hospital, SCRI-huCAR19v2 / Seattle Children's Hospital
Enrollment open, CAR T-Cell Therapy: CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma (clinicaltrials.gov) - Oct 30, 2020
P1/2, N=112, Recruiting, Sponsor: Seattle Children's Hospital
Recruiting --> Suspended Active, not recruiting --> Recruiting
- | SCRI-huCAR19v1 / Seattle Children's Hospital, SCRI-huCAR19v2 / Seattle Children's Hospital
Enrollment closed, CAR T-Cell Therapy: CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma (clinicaltrials.gov) - Feb 25, 2020
P1/2, N=112, Active, not recruiting, Sponsor: Seattle Children's Hospital
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | SCRI-huCAR19v1 / Seattle Children's Hospital, SCRI-huCAR19v2 / Seattle Children's Hospital
Enrollment open, CAR T-Cell Therapy: CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma (clinicaltrials.gov) - Nov 14, 2018
P1/2, N=107, Recruiting, Sponsor: Seattle Children's Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | SCRI-huCAR19v1 / Seattle Children's Hospital, SCRI-huCAR19v2 / Seattle Children's Hospital
New P1/2 trial, CAR T-Cell Therapy: CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma (clinicaltrials.gov) - Sep 26, 2018
P1/2, N=107, Not yet recruiting, Sponsor: Seattle Children's Hospital